Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Report Date: February 24, 2026
Reporting Period: Fourth quarter ended December 31, 2025
This filing serves as a notification that the Company issued a press release regarding its financial results for the fourth quarter of 2025. The detailed results are contained in Exhibit 99.1, which is incorporated by reference but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The provided text does not contain specific numerical values for revenue, net income, operating cash flow, margins, debt levels, or liquidity positions. These figures are located in the referenced press release (Exhibit 99.1) and are not included in the body of this 8-K summary.
Material Changes
Comparison to Prior Period: The filing text does not provide specific data points or percentage changes comparing the fourth quarter of 2025 to prior periods. Investors must refer to the attached press release for year-over-year or quarter-over-quarter performance analysis.
Guidance, Outlook, and Risks
- Management Commentary: The Company hosted a conference call on February 24, 2026, to present business and financial results. A webcast is archived on the Company's website.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties.
- Risk Factors: Risks include ordinary business operations, general economic conditions, and market competition. Specific risk factors are detailed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (filed February 25, 2025).
- Unusual Items: No unusual items or contingencies are explicitly detailed in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 2025 financial figures (revenue, EPS, cash position).
- Access the archived webcast on www.supernus.com for management's detailed commentary on the results.
- Consult the Form 10-K filed on February 25, 2025, for a comprehensive list of risk factors applicable to the forward-looking statements in this report.
- Verify the Company's status as an emerging growth company (indicated as not applicable in this filing).